GTGursaran Pran Talwar

Gursaran Pran Talwar

*This is an algorithmically generated author record based on publicly available information.

Gursaran Pran Talwar has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Survivin targeting triple-fusion vaccine DCSurvivin-LTB inhibits tumor growth in mouse model of triple-negative breast cancer

    by Ambreen Rashid, Anuja Krishnan, Sarika Gupta, Jagdish C. Gupta, G. P. Talwar

    Survivin, an anti-apoptotic protein, plays a pivotal role in cancer progression by disrupting the balance between cell division and apoptosis. We have developed and characterized an anti-Survivin vaccine designed as a triple fusion protein to enhance immunogenicity. In this study, we have evaluated the vaccine’s efficacy in reducing tumor growth using a Survivin expressing 4T1 pre-clinical mouse model of triple-negative breast cancer (TNBC), which is difficult to treat due to its heterogeneous microenvironment, aggressive nature, poor prognosis, and high relapse rates. The recombinant DCSurvivin-LTB protein was purified, adsorbed onto alum, and formulated with Mycobacterium indicus pranii (MIP) before administration to Balb/c mice for dose optimization. The dose that maximized antibody production was selected for efficacy studies in 4T1 tumor-bearing mice in vivo. Vaccination elicited a strong anti-Survivin antibody response and significantly inhibited tumor growth compared with controls. Elevated Granzyme B levels in vaccinated mice indicated activation of the apoptotic pathway, contributing to tumor inhibition. IFN-γ, IL-2 and IL-12 levels were also higher after the vaccination which boosted the immune system to target the cancer cells. Histopathological analysis revealed no observable toxicity or adverse effects on major organs. Immunohistochemical analysis confirmed reduced expression of angiogenesis marker VEGF and increased expression of apoptotic marker Caspase 3. These findings highlight the potential of DCSurvivin-LTB, in combination with MIP, as a promising immunotherapeutic approach for the treatment of metastatic TNBC expressing Survivin.


  • Humanized recombinant immunotoxin targeting hCG demonstrates therapeutic potential for advanced stage difficult to treat cancers

    by Kirti Nain, Kritika Sonar, Sibasis Sahoo, Jagdish C. Gupta, Sonam Grover, Arockiasamy Arulandu, G. P. Talwar

    We report the development of an immunotherapeutic molecule, a humanized immunotoxin, for treating hCG-expressing advanced-stage cancers. PiPP, a high-affinity anti-hCG monoclonal antibody, is used in the immunotoxin for 'homing' hCG-positive cancer cells. The deimmunized (DI) form of α-Sarcin, a fungal-origin toxin that lacks functional T-cell epitopes, is used in the design to ensure minimal immunogenicity of the immunotoxin for repetitive use in humans. A single-chain variable fragment (scFv) of PiPP was constructed by linking the humanized VH and VL regions of the antibody. The scFv part of the antibody was further linked to the toxin α-Sarcin (DI) at the gene level and expressed as a recombinant protein in E. coli. The immunotoxin was purified from the bacterial cell lysate and analyzed for binding and cytotoxicity to hCG-secreting colorectal and pancreatic cancer cells. The results showed that the scFv(PiPP)-Sarcin immunotoxin was able to bind to colorectal and pancreatic cancer cells and killed approximately 85% of the cells. In vivo testing of the immunotoxin produced results similar to those of in vitro testing against colorectal adenocarcinoma-induced tumors. This immunotoxin could be a promising immunotherapeutic agent for treating colorectal, pancreatic and other terminal-stage hCG-expressing cancers.

  • Open Access

    The genetically engineered vaccine against human chorionic gonadotropin enters Phase I/II clinical trials faces a problem, its possible resolution

    by G. P. Talwar, Rohini Sehgal, Mala Shrivastava, R. S. Sharma, Jagdish C. Gupta, Satish K. Gupta, Kamal Buckshee, Priyanka Pal, Kirti Nain, Sunesh Kumar

    Objectives: To determine the causes for formation of nodules in 5 out of 9 women immunized with the genetically engineered vaccine against hCG. Material and Methods: Studies were carried out in C57BL/6 strain of mice. Vaccine was given not only by intradermal but also by intramuscular route. Results: Nodules were formed in mice when vaccine was given by intradermal route but not by intramuscular route. No antibodies were measurable after 1 µg of the Protein version of the vaccine. However the vaccine given at 2 µg dose (equivalent to 388 µg human dose) induced good antibody response in every mouse. Conclusion: Vaccine may be given by intramuscular and not by intradermal route. The dose of the vaccine for women should be at least 300 µg of the Protein version of the vaccine after priming with the DNA version of the vaccine to induce antibody response.

  • Open Access

    A unique vaccine for birth control and treatment of advanced stage cancers secreting ectopically human chorionic gonadotropin

    by Gursaran P. Talwar, Jagdish C. Gupta, Shilpi Purswani, Hemant K. Vyas, Kripa N. Nand, Priyanka Pal, Krishna M. Ella

    This article is a tribute and homage to Gerard Chaouat who invited me to contribute this article. My years in France have remained very memorable to me. Reviewed briefly is the vaccine that was made against human chorionic gonadotropin (hCG) to prevent unwanted pregnancy in sexually active women. It has now been developed as a genetically engineered recombinant vaccine and passed onto industry for its production under good manufacturing practices (GMP) conditions for confirmatory trials. The trials have received the approval of the Drugs Controller General of India. The trials have started but have been interrupted by the coronavirus disease 2019 (COVID-19) pandemic. This vaccine is likely to have another highly beneficial application in the treatment of cancers expressing ectopically hCG.

  • Open Access

    Development of a potent invigorator of immune responses endowed with both preventive and therapeutic properties

    by Gursaran P Talwar, Jagdish C. Gupta, Abu Salim Mustafa, Hemanta K Kar, Kiran Katoch, Shreemanta K Parida, Prabhakara P Reddi, Niyaz Ahmed, Vikram Saini, Somesh Gupta

    This article reviews briefly the making of an immunoprophylactic-cum-immunotherapeutic vaccine against leprosy. The vaccine is based on cultivable, heat-killed atypical mycobacteria, whose gene sequence is now known. It has been named Mycobacterium indicus pranii. It has received the approval of the Drug Controller General of India and the US Food and Drug Administration. Besides leprosy, M. indicus pranii has found utility in the treatment of category II (“difficult to treat”) tuberculosis. It also heals ugly anogenital warts. It has preventive and therapeutic action against SP2/O myelomas. It is proving to be a potent adjuvant for enhancing antibody titers of a recombinant vaccine against human chorionic gonadotropin, with the potential of preventing pregnancy without derangement of ovulation and menstrual regularity in sexually active women.


  • Current status of a unique vaccine preventing pregnancy

    by Gursaran P. Talwar, Kripa N. Nand, Jagdish C. Gupta, Atmaram H. Bandivdekar, Radhey S. Sharma, Nirmal K. Lohiya

    The ability of a vaccine linking beta hCG to a carrier to generate antibodies against hCG, its reversibility and safety was established by Phase I clinical trials conducted in India, Finland, Sweden, Chile and Brazil. Employing a hetero-species dimer (beta hCG-αoLH) linked to tetanus toxoid further improved the immunogenicity of the vaccine. Phase II clinical trials showed that anti-hCG titres above 50 ng/ml prevented pregnancy of sexually active fertile women without derangement of ovulation and menstrual regularity. On decline of antibodies, women conceived again to give birth to normal progeny. A genetically engineered vaccine consisting of beta hCG linked to B subunit of heat labile enterotoxin of E. coli has been made. It is expressed as DNA as well as protein. Priming with DNA followed by protein version of the vaccine generates very high titres against hCG in mice. Extensive toxicology studies in 2 species of rodents, and marmosets have shown complete safety of the vaccine. The vaccine is cleared for Clinical trials by the National Review committee on Genetic Manipulation and Drugs Controller General of India.


  • Immuno-interception of Fertility: Current Status of Vaccines Developed Against hCG and LHRH

    by Gursaran P. Talwar, Shilpi Purswani, Jagdish Chandra Gupta, Hemant Kumar Vyas

  • Open Access

    Survivin: a unique target for tumor therapy

    by Himani Garg, Prerna Suri, Jagdish C. Gupta, G. P. Talwar, Shweta Dubey

    Survivin is the smallest member of the Inhibitor of apoptosis (IAP) family of proteins, involved in inhibition of apoptosis and regulation of cell cycle. These functional attributes make Survivin a unique protein exhibiting divergent functions i.e. regulating cell proliferation and cell death. Expression pattern of Survivin is also distinctive; it is prominently expressed during embryonal development, absent in most normal, terminally differentiated tissues but upregulated in a variety of human cancers. Expression of Survivin in tumours correlates with not only inhibition of apoptosis and a decreased rate of cell death, but also resistance to chemotherapy and aggressiveness of tumours. Therefore, Survivin is an important target for cancer vaccines and therapeutics. Survivin has also been found to be prominently expressed on both human and embryonic stem cells and many somatic stem cell types indicating its yet unexplored role in stem cell generation and maintenance. Overall, Survivin emerges as a molecule with much wider role in cellular homeostasis. This review will discuss various aspects of Survivin biology and its role in regulation of apoptosis, cell division, chemo-resistance and tumour progression. Various molecular and immunotherapeutic approaches targeting Survivin will also be discussed.